Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 20, 2013

View Archived Issues

Researchers establish FNAIT symptoms in mice

Novel OGA inhibitors show efficacy in model of tau aggregation

Retrophin selects new clinical development candidate, RE-034

Gilead Sciences reports data from phase III studies of fixed-dose sofosbuvir and ledipasvir

InSite Vision reports confirmatory phase III data for BromSite

Mylan acquires rights to novel LAMA compound from Pfizer

Merck Serono enters into agreement with the Spanish National Cancer Research Center

Euroscreen begins phase I trial of ESN-364

Biocon and Quark Pharmaceuticals to develop novel siRNA therapeutics

Novel agents for protozoal infections presented by U.S. and Colombian team

Nippon Shinyaku prepares new tyrosine protein kinase inhibitors

Meiji Seika Pharma divulges novel beta-lactamase inhibitors

Takeda Pharmaceutical discloses novel tyrosine-protein kinase inhibitors

Novel botulinum neurotoxin polypeptides prepared by Harvard College

Merck & Co. presents novel PET imaging agents for AD

Atara Biotherapeutics secures funding to accelerate lead program development

AstraZeneca to acquire Bristol-Myers Squibb's diabetes alliance assets

Phase I results demonstrate JNJ-40346527 to be safe in patients with refractory Hodgkin's lymphoma

Crossbeta Biosciences and AdAlta collaborate on i-body technology for Alzheimer's disease

Potent ROR-gamma inverse agonist demonstrates efficacy in a murine model of arthritis

Daiichi Sankyo submits supplemental NDA in Japan for Lixiana

Almirall to acquire Aqua Pharmaceuticals

Cellmid provides data from CK3000 study program

Inavir Dry Powder Inhaler approved for influenza prophylaxis in Japan

NIH announces new preclinical projects under BrIDGs program

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...